智通财经APP讯,复宏汉霖(02696)发布公告,公司于2025年4月25日与Alvogen Korea Co., Ltd.订立一份许可协议,据此,公司向 Alvogen Korea授出独家许可,供其于韩国于领域内商业化汉斯状® (斯鲁利单抗注射液)。
本次合作将有助于进一步拓展公司产品的海外市场,增强公司产品在国际市场的可及性和认可度,并为公司收入的持续提升创造条件。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.